Related references
Note: Only part of the references are listed.GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models
Robert J. Torphy et al.
NATURE COMMUNICATIONS (2022)
Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis
Gao Liu et al.
CELL DEATH & DISEASE (2021)
CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer
Yingying Cao et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
Jian Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala et al.
NATURE REVIEWS CANCER (2021)
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Imran G. House et al.
CLINICAL CANCER RESEARCH (2020)
Directing Traffic: How to Effectively Drive T Cells into Tumors
Annabelle J. Anandappa et al.
CANCER DISCOVERY (2020)
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
Khalil Choucair et al.
CANCER GENE THERAPY (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma
M. J. M. van Velzen et al.
CANCER TREATMENT REVIEWS (2020)
Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells
Hyun Jung Hwang et al.
CANCER LETTERS (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
CD8+ T cell states in human cancer: insights from single-cell analysis
Anne M. Van der Leun et al.
NATURE REVIEWS CANCER (2020)
The Role of ACKR3 in Breast, Lung, and Brain Cancer
Maria Neves et al.
MOLECULAR PHARMACOLOGY (2019)
The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw et al.
CANCER RESEARCH (2019)
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Stergios Boussios et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Methods of measurement for tumor mutational burden in tumor tissue
Barbara Melendez et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Migrating into the Tumor: a Roadmap for T Cells
Lieke L. van der Woude et al.
TRENDS IN CANCER (2017)
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li et al.
CANCER RESEARCH (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Tumor microenvironment and therapeutic response
Ting Wu et al.
CANCER LETTERS (2017)
Atypical Chemokine Receptors and Their Roles in the Resolution of the inflammatory Response
Raffaella Bonecchi et al.
FRONTIERS IN IMMUNOLOGY (2016)
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
Yu Zhang et al.
JAMA ONCOLOGY (2016)
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Jason W. Griffith et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Share Paper
